Table S2.
Dose–response associations between the use of individual NSAIDs and the risk of all-cause mortality in patients with end-stage renal disease
| Cumulative NSAID use | Number of mortality | Person-years | Incidence rate (95% CI) (per 100 person-years) | Crude HR(95% CI) | Adjusted HR (95% CI) | |||
|---|---|---|---|---|---|---|---|---|
| Diclofenac | ||||||||
| 0 DDDs (0 g) | 810 | 9967 | 8.1 | (7.6–8.7) | 1.00 | (reference) | 1.00 | (reference) |
| 1−30 DDDs (0.1−3 g) | 599 | 5656 | 10.6 | (9.8–11.5) | 1.34 | (1.19–1.50) | 1.44 | (1.29–1.62) |
| 31−90 DDDs (3.1−9 g) | 77 | 851 | 9.1 | (7.2–11.3) | 1.17 | (0.92–1.50) | 1.28 | (1.00–1.64) |
| >90 DDDs (>9 g) | 29 | 231 | 12.6 | (8.7–18.1) | 1.68 | (1.15–2.45) | 1.95 | (1.33–2.86) |
| Celecoxib | ||||||||
| 0 DDDs (0 g) | 1170 | 14267 | 8.2 | (7.7–8.7) | 1.00 | (reference) | 1.00 | (reference) |
| 1−30 DDDs (0.2−6 g) | 222 | 1565 | 14.2 | (12.4–16.2) | 1.77 | (1.53–2.05) | 1.68 | (1.44–1.95) |
| 31−90 DDDs (6.1−18 g) | 76 | 474 | 16.0 | (12.8–20.1) | 1.99 | (1.58–2.52) | 1.56 | (1.22–1.98) |
| >90 DDDs (>18 g) | 47 | 399 | 11.8 | (8.9–15.7) | 1.50 | (1.11–2.02) | 1.18 | (0.88–1.60) |
| Etoricoxib | ||||||||
| 0 DDDs (0 g) | 1442 | 16321 | 8.8 | (8.4–9.3) | 1.00 | (reference) | 1.00 | (reference) |
| 1−30 DDDs (0.06−1.8 g) | 53 | 237 | 22.4 | (17.1–29.3) | 2.53 | (1.92–3.34) | 1.95 | (1.47–2.57) |
| 31−90 DDDs (1.9−5.4 g) | 13 | 93 | 14.0 | (8.1–24.1) | 1.60 | (0.93–2.78) | 1.19 | (0.69–2.07) |
| >90 DDDs (>5.4 g) | 7 | 54 | 13.0 | (6.2–27.2) | 1.48 | (0.70–3.11) | 1.40 | (0.66–2.96) |
Notes: Adjusted HRs were computed after adjustment of age, sex, residence area, types of dialysis, baseline comorbidities, and opioid use.
Abbreviations: DDD, defined daily dose.